Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma
暂无分享,去创建一个
[1] K. Soo,et al. Elderly Patients with Advanced Head and Neck Carcinoma: Does Aggressive Treatment Result in Better Outcomes? , 2018, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[2] S. Bentzen,et al. Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database. , 2018, Oral oncology.
[3] S. Krishnan,et al. Frailty in geriatric head and neck cancer: A contemporary review , 2018, The Laryngoscope.
[4] R. Weber,et al. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[5] G. Ruoppolo,et al. Late radiation-associated dysphagia in head and neck cancer patients: evidence, research and management. , 2018, Oral oncology.
[6] V. Tombolini,et al. Osteoradionecrosis and intensity modulated radiation therapy: An overview. , 2016, Critical reviews in oncology/hematology.
[7] R. Steenbakkers,et al. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[8] V. Tombolini,et al. Treatment improvement and better patient care: which is the most important one in oral cavity cancer? , 2014, Radiation oncology.
[9] H. Cohen,et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] E. Yorke,et al. Use of normal tissue complication probability models in the clinic. , 2010, International journal of radiation oncology, biology, physics.
[11] P. Sanghera,et al. Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[12] J. Pignon,et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[13] M. Poulsen,et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[14] Byung-Joo Lee,et al. Induction chemotherapy of docetaxel and Cisplatin for the elderly patients with squamous cell carcinoma of the head and neck. , 2007, Cancer research and treatment : official journal of Korean Cancer Association.
[15] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[16] Edward L Spitznagel,et al. Prognostic importance of comorbidity in a hospital-based cancer registry. , 2004, JAMA.
[17] Peijun Chen,et al. The Mini‐Cog as a Screen for Dementia: Validation in a Population‐Based Sample , 2003, Journal of the American Geriatrics Society.
[18] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[19] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .